AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7049585
Drug: Dextropropoxyphene (65
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextropropoxyphene (65 mg) plus Paracetamol (650 mg)
Trial: 22467013
Drug: Chemotherapy (cytostatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (cytostatic and genotoxic drugs)
Trial: 16116005
Drug: Spinal anesthesia
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal anesthesia (2.2 mL of 0.5% hyperbaric bupivacaine plus 0.2 mg morphine)
Trial: 16116005
Drug: Epidural anesthesia
RxNorm normalized name: Epidural Anesthesia Tray
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epidural anesthesia (2% lidocaine with epinephrine 1:400,000, 18‐23 mL, followed by 3 mg of morphine after delivery)
Trial: 10027033
Drug: (R)-ketamine 1
RxNorm normalized name: (r)-(+)-ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (R)-ketamine 1 mg/kg (PRE group)
Trial: 10027033
Drug: Saline followed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline followed by (R)-ketamine 1 mg/kg (POST group)
Trial: 10027033
Drug: Analgesic consumption
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analgesic consumption at 24 h and 7 days (all groups)
Trial: 1492006
Drug: ciprofloxacin 500
RxNorm normalized name: ciprofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ciprofloxacin 500 mg twice/day for 10 days
Trial: 1492006
Drug: placebo twice/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo twice/day for 10 days
Trial: 28968870
Drug: Hydrochlorothiazide 12.5
RxNorm normalized name: hydrochlorothiazide 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide 12.5 mg once daily for 4 weeks
Trial: 28968870
Drug: Valsartan 80
RxNorm normalized name: valsartan 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 80 mg once daily for 4 weeks
Trial: 28968870
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of both drugs
Trial: 15248440
Drug: Acetylcysteine (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetylcysteine (600 mg in the morning and evening before examination) with intravenous saline hydration
Trial: 9663358
Drug: Hylan G-F
RxNorm normalized name: hylan G-F 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hylan G-F 20 (2 mL, three intra-articular injections, 1 week apart)
Trial: 9663358
Drug: Physiologic buffered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiologic buffered saline solution (2 mL, three injections at the same intervals)
Trial: 9663358
Drug: Physiologic buffered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiologic buffered saline solution
Trial: 2856597
Drug: cimetidine 300
RxNorm normalized name: cimetidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cimetidine 300 mg QID
Trial: 2856597
Drug: cimetidine 800
RxNorm normalized name: cimetidine 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cimetidine 800 mg HS
Trial: 2856597
Drug: ranitidine 300
RxNorm normalized name: ranitidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ranitidine 300 mg HS
Trial: 25705653
Drug: DBM injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DBM injection (n = 14)
Trial: 25705653
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment without injection (n = 15)
Trial: 23159586
Drug: Brief smoking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief smoking cessation intervention plus nicotine replacement therapy
Trial: 21176029
Drug: Uridine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uridine (2 g)
Trial: 12800416
Drug: Digoxin combined
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Digoxin combined with 20 ml of Shengmai Injection (SMI)
Trial: 12800416
Drug: Digoxin combined
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Digoxin combined with 40 ml of Shengmai Injection (SMI)
Trial: 12800416
Drug: Digoxin combined
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Digoxin combined with 60 ml of Shengmai Injection (SMI)
Trial: 12800416
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no Shengmai Injection)
Trial: 9002785
Drug: Braun Oral‐B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Braun Oral‐B Plaque Remover‐D7
Trial: 9002785
Drug: Braun Oral‐B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Braun Oral‐B Ultra Plaque Remover‐D9
Trial: 4077545
Drug: Self-Management Training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-Management Training Program (SCRPA) for school-age children (ages 6-14), consisting of eight 90-minute classes for both child and parent(s) scheduled twice a week for 4 weeks.
Trial: 4077545
Drug: Self-Management Training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-Management Training Program (SCRPA) for preschool children (ages 2-5), consisting of six 1-hour classes scheduled twice a week for 3 weeks.
Trial: 31408467
Drug: Novel drink
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel drink powder (4 g betaine, 800 μg folic acid, 5.2 μg vitamin B12, and 2.8 mg vitamin B2)
Trial: 31408467
Drug: UNIMMAP (widely
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UNIMMAP (widely used multiple micronutrient tablet containing 15 micronutrients)
Trial: 22873117
Drug: Ringer's solution
RxNorm normalized name: Ringer's solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer's solution (control site)
Trial: 22873117
Drug: Ketorolac (COX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac (COX pathway inhibitor)
Trial: 17259476
Drug: 4 g
RxNorm normalized name: CTX4 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g HV‐HPMC
Trial: 17259476
Drug: 8 g
RxNorm normalized name: Theranost 68 Ga Rgd
DrugBank: NODAGA-THERANOST Ga-68 (DB16940)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 g HV‐HPMC
Trial: 17259476
Drug: Control meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control meal (8 g cellulose)
Trial: 15734080
Drug: Amoxicillin-sulbactam
RxNorm normalized name: amoxicillin / sulbactam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin-sulbactam
Trial: 7762842
Drug: Adenosine infusion,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenosine infusion, 80 micrograms.kg-1.min-1
Trial: 2268865
Drug: Slow‐K (wax-matrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow‐K (wax-matrix tablet)
Trial: 2268865
Drug: K‐Dur (microencapsulated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: K‐Dur (microencapsulated tablet)
Trial: 78384
Drug: E. coli
RxNorm normalized name: E. coli antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E. coli H‐10407 (C.F.A.+) at a dose of 10(8)
Trial: 16306137
Drug: Polyethylene glycol
RxNorm normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyethylene glycol (PEG) electrolyte balanced solution, 29.5 g daily for 7 days
Trial: 10786346
Drug: Topical diclofenac
RxNorm normalized name: diclofenac Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical diclofenac emulsion gel applied every 8 hours for 48 hours
Trial: 10786346
Drug: Oral diclofenac
RxNorm normalized name: diclofenac Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral diclofenac 75 mg p.o. every 12 hours for 48 hours
Trial: 9381637
Drug: Likopide (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Likopide (10 mg tablets, orally, twice daily for 3 days, followed by a 3-day interval, then 3 days of treatment)
Trial: 8239057
Drug: Padma 28
RxNorm normalized name: Padma Flower
DrugBank: Nelumbo nucifera flower (DB14333)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Padma 28 (340 mg, two tablets bid)
Trial: 3919831
Drug: Cisplatin 120
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 120 mg intravenously
Trial: 3919831
Drug: Cyclophosphamide 2
RxNorm normalized name: cyclophosphamide 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide 2 g intravenously
Trial: 27852286
Drug: Best medical
RxNorm normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best medical treatment plus extracranial-intracranial (EC-IC) bypass surgery
Trial: 25130149
Drug: Low-dose hCG
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose hCG (200 IU daily)
Trial: 20090953
Drug: Self-Administered Questionnaire
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-Administered Questionnaire (SAQ)
Trial: 17392718
Drug: St John's
RxNorm normalized name: St john's wort
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: St John's wort (SJW) 900 mg daily for 12 days
Trial: 15629592
Drug: High-source strength
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-source strength implants (0.76 microGy/m(2)/h)
Trial: 15629592
Drug: Low-source strength
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-source strength implants (0.4 microGy/m(2)/h)
Trial: 15629592
Drug: High-source strength
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-source strength implants
Trial: 15629592
Drug: Low-source strength
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-source strength implants
Trial: 7027750
Drug: Initial dose
RxNorm normalized name: PEANUT ALLER INITIAL DOSE ORAL,PKT,13
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial dose of glipizide (5 mg p.o.)
Trial: 7027750
Drug: Long-term treatment
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term treatment with glipizide (range 7.5‐20 mg, mean 10.4 mg)
Trial: 7027750
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose regime
Trial: 7027750
Drug: Three-part divided
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-part divided dose regime
Trial: 7027750
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose and divided dose regimes
Trial: 31634870
Drug: Silymarin 140
RxNorm normalized name: silymarin 140 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silymarin 140 mg every 8 hours for 7 days
Trial: 31634870
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving standard treatments
Trial: 31043521
Drug: Balovaptan 4
RxNorm normalized name: Balovaptan
DrugBank: Balovaptan (DB14823)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balovaptan 4 mg
Trial: 31043521
Drug: Balovaptan 10
RxNorm normalized name: Balovaptan
DrugBank: Balovaptan (DB14823)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balovaptan 10 mg
Trial: 25482469
Drug: Local infiltration
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local infiltration of 20 mL bupivacaine 0.25%
Trial: 25482469
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group (20 mL saline 0.9%)
Trial: 16131291
Drug: Stimulation acupressure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stimulation acupressure treatment
Trial: 16131291
Drug: Relaxation acupressure
RxNorm normalized name: ACUPRESSURE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relaxation acupressure treatment
Trial: 23981104
Drug: Metformin 850
RxNorm normalized name: metFORMIN 850 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 850 mg (one to three times daily)
Trial: 18548841
Drug: Ketamine (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (0.2 mL injection)
Trial: 18548841
Drug: Placebo (buffered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (buffered isotonic saline, 155 mmol/L)
Trial: 16800990
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no specific medicine)
Trial: 10550755
Drug: Fexofenadine HCl
RxNorm normalized name: fexofenadine HCl
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fexofenadine HCl 20 mg twice a day
Trial: 10550755
Drug: Fexofenadine HCl
RxNorm normalized name: fexofenadine HCl
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fexofenadine HCl 60 mg twice a day
Trial: 10550755
Drug: Fexofenadine HCl
RxNorm normalized name: fexofenadine HCl
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fexofenadine HCl 120 mg twice a day
Trial: 10550755
Drug: Fexofenadine HCl
RxNorm normalized name: fexofenadine HCl
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fexofenadine HCl 240 mg twice a day
Trial: 9479614
Drug: d,l-fenfluramine (FEN)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d,l-fenfluramine (FEN) 60 mg
Trial: 9479614
Drug: drug-free unipolar
RxNorm normalized name: quetiapine
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: drug-free unipolar patients
Trial: 7524593
Drug: C1 inhibitor
RxNorm normalized name: C1 INHIBITOR
DrugBank: Conestat alfa (DB09228)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: C1 inhibitor plasma concentrate 3000 U i.v.
Trial: 3555690
Drug: Dipyridamole 200
RxNorm normalized name: dipyridamole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyridamole 200 mg b.d. for 48 h pre-operatively and dipyridamole 200 mg b.d. with aspirin 300 mg daily for 6 weeks after surgery
Trial: 3555690
Drug: Prosthetic dipyridamole
RxNorm normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prosthetic dipyridamole and aspirin group
Trial: 3555690
Drug: Dipyridamole and
RxNorm normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dipyridamole and aspirin group
Trial: 30753323
Drug: Cashew nut
RxNorm normalized name: Cashew nut
DrugBank: Cashew (DB10653)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cashew nut phase (1.5 servings or 42 g of cashews/day)
Trial: 29102979
Drug: Febuxostat 80
RxNorm normalized name: febuxostat 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Febuxostat 80 mg once daily
Trial: 20015430
Drug: Tunnel thread-drawing
RxNorm normalized name: Drawing Salve
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tunnel thread-drawing therapy
Trial: 17047542
Drug: Manual Physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual Physical Therapy, Exercise, and Walking Group
Trial: 15008862
Drug: Polidocanol (POL)
RxNorm normalized name: Polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Polidocanol (POL) 0.25% solution
Trial: 9215605
Drug: Itasetron hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itasetron hydrochloride (0.5, 1, 2, 4, and 8 mg twice daily)
Trial: 9215605
Drug: Ondansetron (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (8 mg twice daily)
Trial: 3301986
Drug: Polymerized ragweed
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polymerized ragweed (PRW) immunotherapy, 15 weekly injections totaling 1359 allergy units
Trial: 3301986
Drug: Polymerized ragweed
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polymerized ragweed (PRW) immunotherapy
Trial: 18705320
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen treatment (HBO), started 3 days after operation
Trial: 18705320
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no HBO treatment)
Trial: 12831383
Drug: Primary care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary care buprenorphine treatment
Trial: 12831383
Drug: Specialist clinic
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specialist clinic buprenorphine treatment
Trial: 8156354
Drug: Octreotide 0.1
RxNorm normalized name: octreotide 0.1 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide 0.1 mg every 8 h
Trial: 26255876
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment for excessive gingival exposure by septum cartilage reinforcement and additional extension using an autologous cartilage graft or ePTFE implant.
Trial: 23893461
Drug: Trametinib (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trametinib (2 mg) administered in a fed state
Trial: 23893461
Drug: Trametinib (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trametinib (2 mg) administered in a fasted state
Trial: 17000959
Drug: Interferon beta-1a
RxNorm normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon beta-1a 44 microg subcutaneously three times weekly (TIW)
Trial: 17000959
Drug: Interferon beta-1a
RxNorm normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon beta-1a 22 microg subcutaneously three times weekly (TIW)
Trial: 11097538
Drug: Intraoperative morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative morphine (0.1 mg x kg(‐1))
Trial: 11097538
Drug: Postoperative morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative morphine (0.1 mg x kg(‐1))
Trial: 8760978
Drug: PTA plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTA plus medical treatment (n = 30)
Trial: 8760978
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment alone (control group, n = 32)
Trial: 1581268
Drug: Bupivacaine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine with epinephrine (5 micrograms/ml)
Trial: 1581268
Drug: Unilateral pleural
RxNorm normalized name: PLEURAL DRAINAGE KIT ROCKET #51411
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unilateral pleural infusion of bupivacaine
Trial: 1581268
Drug: Bilateral pleural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral pleural infusion of bupivacaine
Trial: 27129118
Drug: SFDAC intranasal
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SFDAC intranasal spray (up to 3,200 µg)
Trial: 22121129
Drug: golimumab 100
RxNorm normalized name: golimumab 100 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: golimumab 100 mg + MTX (Group 3)
Trial: 19945102
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment with an angular stable interlocking implant (25 patients)
Trial: 19945102
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment (25 patients)
Trial: 17380402
Drug: Bowel preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bowel preparation consisting of an isotonic solution containing polyethylene glycol and simethicone (200 ml given 30 min before capsule, followed by 100 ml of prep and 100 ml of water; additional 100 ml of prep given 45 and 75 min later)
Trial: 17380402
Drug: Control administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control administration of 100 ml of water and no simethicone
Trial: 10434485
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate (MPH) at an average dose of 0.5 mg/kg twice daily
Trial: 8871266
Drug: Policosanol 5
RxNorm normalized name: policosanol 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Policosanol 5 mg twice-a-day
Trial: 2273545
Drug: Morphine hydrochloride
RxNorm normalized name: Morphine hydrochloride
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine hydrochloride 2 mg in 8 ml of normal saline administered epidurally one to two hours before the end of surgery.
Trial: 2273545
Drug: Morphine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine administered epidurally at different spinal levels (Th11-12, L2-3, caudal).
Trial: 2273545
Drug: Morphine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine administered epidurally.
Trial: 6104564
Drug: Primidolol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primidolol (50 mg or 100 mg)
Trial: 27836933
Drug: Regorafenib (starting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regorafenib (starting doses: 160 mg or lower)
Trial: 27836933
Drug: Regorafenib (lower
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regorafenib (lower dose)
Trial: 27836933
Drug: Regorafenib (overall
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regorafenib (overall treatment)